US Dollar vs MXN

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

MRK Merck and Co Inc

125.08

-0.29 (-0.23%)

Última actualización: 13:21:32

Retrasado por 15 minutos

Sutro Biopharma and Merck extend research term for cytokine derivative program

To read the full story on Seeking Alpha, click here.

Merck (NYSE:MRK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Haga Click aquí para más Gráficas Merck.

Merck (NYSE:MRK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024

Haga Click aquí para más Gráficas Merck.

Noticias sobre Merck and Co Inc MRK

Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
Miércoles 10 de Abril 2024 (1 semana hace) • IH Market News

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Jueves 4 de Abril 2024 (2 semanas hace) • Business Wire

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Miércoles 3 de Abril 2024 (2 semanas hace) • Business Wire

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Lunes 1 de Abril 2024 (2 semanas hace) • Business Wire

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Jueves 28 de Marzo 2024 (3 semanas hace) • Business Wire

GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News
Miércoles 27 de Marzo 2024 (3 semanas hace) • IH Market News

FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Martes 26 de Marzo 2024 (3 semanas hace) • Business Wire

Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Jueves 21 de Marzo 2024 (4 semanas hace) • Business Wire

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Martes 19 de Marzo 2024 (1 mes hace) • Business Wire

FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
Viernes 15 de Marzo 2024 (1 mes hace) • PR Newswire (US)

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Viernes 15 de Marzo 2024 (1 mes hace) • Business Wire

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Miércoles 13 de Marzo 2024 (1 mes hace) • Business Wire

Más de Merck and Co Inc Artículos de Noticias

Financial Select Sector

Deutsche Telekom (QX)

Verizon Communications

Bank of America

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones